SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.

The movement appears linked to the company being highlighted as a key healthcare pick in a prominent June investment strategy report. The report details SKB BIO's focus on ADC drug development and its landmark partnership with Merck & Co. for its pipeline asset, sac-TMT. Positive clinical data and the initiation of larger-than-expected global Phase III trials by Merck have bolstered market confidence in the drug's potential.

Analysts note that as Chinese clinical data continues to accumulate, sac-TMT's Best-in-Class profile is becoming clearer. With Merck rapidly advancing global registrational studies, key data readouts are approaching, supporting an estimated peak global sales potential of $15 billion for the asset. The company is expected to achieve profitability in 2027, with the clinical value of sac-TMT likely to increase significantly in 2026.